Compound Detail
CHEMBL92870
LIDOFLAZINE 🧪 Phase II
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
🧪 Phase II
Basic Information
| ChEMBL ID | CHEMBL92870 |
| Name | LIDOFLAZINE |
| Phase | Phase II |
| Structure Type | MOL |
| InChI Key | ZBIAKUMOEKILTF-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
7
Targets
9
Activities
3
Assay Types
0
PK Parameters
20
Publications
7
Known Names
1
Indications
Molecular Properties
491.6
MW (Da)
5.75
ALogP
3
HBA
1
HBD
35.6
PSA (Ų)
0.41
QED
1
Ro5 Violations
9
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| Chirality | Achiral |
Indications
Cardiovascular Diseases
ATC Classification
C08EX01
lidoflazine
Level 1: CARDIOVASCULAR SYSTEM
Level 2: CALCIUM CHANNEL BLOCKERS
Activity Summary
IC50 6 meas. best 7.8
Ki 2 meas. best 7.11
Kd 1 meas. best 7.5
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Voltage-gated inwardly rectifying potassium channel KCNH2 CHEMBL240 | IC50 | 7.8 | 7.8 | 15.8 | 2 |
| Oryctolagus cuniculus CHEMBL374 | Kd | 7.5 | 7.5 | 31.6 | 1 |
| Sodium channel alpha subunits; brain (Types I, II, III) CHEMBL2095171 | Ki | 7.11 | 7.11 | 77.0 | 1 |
| Equilibrative nucleoside transporter 1 CHEMBL1997 | Ki | 6.55 | 6.55 | 279.9 | 1 |
| Sodium channel protein type 2 subunit alpha CHEMBL3399 | IC50 | 5.62 | 5.62 | 2400.0 | 1 |
| Equilibrative nucleoside transporter 1 CHEMBL1997 | IC50 | 5.3 | 5.3 | 4954.0 | 1 |
| Unchecked CHEMBL612545 | IC50 | 5.03 | 5.03 | 9370.0 | 1 |
| SARS-CoV-2 CHEMBL4303835 | IC50 | 4.76 | 4.76 | 17390.0 | 1 |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| - | 10.6019/CHEMBL4651402 | SARS-CoV-2 | 4 |
| 37468498 | 10.1038/s41467-023-40064-9 | Nuclear receptor subfamily 1 group I member 2 | 3 |
| 17636949 | 10.1021/jm070311l | Equilibrative nucleoside transporter 1 | 3 |
| 37468498 | 10.1038/s41467-023-40064-9 | Androgen receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Beta-2 adrenergic receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Beta-1 adrenergic receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Gamma-aminobutyric acid receptor subunit alpha-1 | 2 |
| - | 10.6019/CHEMBL4808148 | Histone deacetylase 6 | 2 |
| - | 10.6019/CHEMBL4651402 | Vero C1008 | 2 |
| - | 10.6019/CHEMBL4495565 | SARS-CoV-2 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Muscarinic acetylcholine receptor M2 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Cannabinoid receptor 1 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | 5-hydroxytryptamine receptor 2A | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Alpha-1A adrenergic receptor | 2 |
| - | 10.21203/rs.3.rs-23951/v1 | SARS-CoV-2 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Progesterone receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | 5-hydroxytryptamine receptor 2B | 2 |
| 1920352 | 10.1021/jm00114a009 | Rattus norvegicus | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Alpha-2A adrenergic receptor | 2 |
| 38318365 | 10.1016/j.isci.2024.108907 | Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 | 1 |
Data from ChEMBL 36 via Core Engine